JPRN-UMIN000046791已完成未知
A randomized, placebo-controlled, double-blind, parallel-group study of the skin-protective effects of crocetin against UV exposure - A randomized, placebo-controlled, double-blind, parallel-group study of the skin-protective effects of crocetin against UV exposure
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 30years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. smoker 2. patients with a history of atopic dermatitis or a predisposition to atopy 3. those who have factors on the skin of the evaluation site that may affect the results of the test 4. those who have been diagnosed as photosensitive 5. those who have undergone or will undergo cosmetic procedures on the evaluation site 6. those who have undergone any special skin care treatment within the past 4 weeks, or plan to do so during the examination period 7. participants who have continuously used skin care products or health foods that advocate or emphasize efficacy similar to or related to the efficacy to be studied in this study 8. those who have changed or newly started using health food products or basic cosmetics or sunscreen products within the past four weeks 9. those who have been or will be exposed to ultraviolet radiation beyond their daily activities within the past 4 weeks 10. those who may be allergic to food 11. those who have been taking medicines which are indicated for the treatment of freckles, pigmentation due to sunburn, and melasma 12. those who work night shifts or day/night shifts 13. those who are undergoing medical treatment for the treatment or prevention of disease at the time of obtaining consent, or those who are judged to be in need of treatment 14. those who are taking drugs that affect the photosensitivity of the skin 15. those who continuously use or take anti-inflammatory drugs at least once a month 16. participants who had a history of serious diseases. 17. undergoing hormone replacement therapy for menopause or postmenopausal women, or those who have not been under treatment for at least 6 months 18. those with a history of alcohol or drug dependence. 19. pregnant or lactating at the time of consent, or who wish to become pregnant during the study period 20. those who have participated in other human studies within the past 4 weeks 21. those who are judged as unsuitable to participate in the study by the principal investigator
研究者
相似试验
进行中（未招募）
1 期
A 2-part trial to learn more about how BAY1817080 works, how safe it is, and what the right dose is for participants with diabetic neuropathic paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2020-002066-14-HUBayer AG440
进行中（未招募）
1 期
A 2-part trial to learn more about how BAY1817080 works, how safe it is, and what the right dose is for participants with diabetic neuropathic paieuropathic pain associated with diabetic peripheral neuropathyMedDRA version: 21.1Level: LLTClassification code 10067547Term: Diabetic peripheral neuropathic painSystem Organ Class: 100000004852EUCTR2020-002066-14-DKBayer AG440
进行中（未招募）
1 期
A study to test whether study drug BAY1128688 brings pain relief to women with endometriosis and if so to get a first idea which dose(s) work best.MedDRA version: 20.0Level: LLTClassification code 10014788Term: Endometriosis related painSystem Organ Class: 10038604 - Reproductive system and breast disordersMedDRA version: 20.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2017-000244-18-ATBayer AG120
已完成
不适用
A randomized, placebo-controlled, double-blind, parallel-group trial of the improvement in ocular function with continued lutein intakeHealthy subjectsJPRN-UMIN000033854HUMA R&D CORP62
进行中（未招募）
1 期
A Phase 2a, randomized, placebo-controlled, double-blind study to investigate REM0046127 in mild to moderate Alzheimer's diseaseMedDRA version: 20.0Level: HLTClassification code 10001897Term: Alzheimer's disease (incl subtypes)System Organ Class: 100000004852Alzheimer's DiseaseEUCTR2022-000080-43-ESreMYND60